Payment overview · 2025
General Payments
$162.52
8 reported records · 8 companies
Healthcare provider profile · identity verified
Mark Edward Silver, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKINGS, OR · NPI 1639178114
Verified facts
What the public records show
CMS Open Payments records show Mark Edward Silver, MD received $162.52 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.23 | 18.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.90 | 13.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.19 | 13.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.83 | 12.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.74 | 11.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.36 | 11.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.28 | 10.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.53 | 7 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 15 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
43 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 96 |
| Omeprazole | Omeprazole | 393 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 365 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 103 |
| Gabapentin | Gabapentin | 320 | 68 |
| Losartan Potassium | Losartan Potassium | 289 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 47 |
| Lisinopril | Lisinopril | 208 | 53 |
| Trazodone Hcl | Trazodone Hcl | 206 | 40 |
| Metformin Hcl Er | Metformin Hcl | 188 | 53 |
| Eliquis | Apixaban | 182 | 40 |
| Meloxicam | Meloxicam | 179 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 48 |
| Potassium Chloride | Potassium Chloride | 144 | 46 |
| Furosemide | Furosemide | 135 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 33 |
| Tramadol Hcl | Tramadol Hcl | 112 | 22 |
| Sertraline Hcl | Sertraline Hcl | 109 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 33 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 96 | suppressed |
| Glimepiride | Glimepiride | 96 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 22 |
| Atenolol | Atenolol | 86 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 27 |
| Bupropion Xl | Bupropion Hcl | 83 | 16 |
| Lorazepam | Lorazepam | 83 | 26 |
| Pregabalin | Pregabalin | 83 | 20 |
| Carvedilol | Carvedilol | 80 | 18 |
| Ibuprofen | Ibuprofen | 79 | 22 |
| Allopurinol | Allopurinol | 76 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 27 |
| Simvastatin | Simvastatin | 75 | 25 |
| Warfarin Sodium | Warfarin Sodium | 74 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 19 |
| Alprazolam | Alprazolam | 72 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 11 |
| Dexamethasone | Dexamethasone | 68 | 51 |
| Estradiol | Estradiol | 66 | 20 |
| Celecoxib | Celecoxib | 64 | 16 |
| Prednisone | Prednisone | 62 | 42 |
| Spironolactone | Spironolactone | 61 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | suppressed |
| Valsartan | Valsartan | 61 | 20 |
| Jardiance | Empagliflozin | 58 | 15 |
| Ozempic | Semaglutide | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 14 |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 28 |
| Baclofen | Baclofen | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Azithromycin | Azithromycin | 52 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 18 |
| Digoxin | Digoxin | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 43 | 33 |
| Finasteride | Finasteride | 42 | 11 |
| Fluconazole | Fluconazole | 42 | 24 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 19 |
| Famotidine | Famotidine | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Fentanyl | Fentanyl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Diazepam | Diazepam | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Haloperidol | Haloperidol | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.52 · 8 records | GlaxoSmithKline, LLC. | AREXVY, BREZTRI, JARDIANCE, LEQVIO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error